NO326216B1 - Et universalt anvendelig blodplasma og fremgangsmate for fremstilling derav. - Google Patents
Et universalt anvendelig blodplasma og fremgangsmate for fremstilling derav. Download PDFInfo
- Publication number
- NO326216B1 NO326216B1 NO20000578A NO20000578A NO326216B1 NO 326216 B1 NO326216 B1 NO 326216B1 NO 20000578 A NO20000578 A NO 20000578A NO 20000578 A NO20000578 A NO 20000578A NO 326216 B1 NO326216 B1 NO 326216B1
- Authority
- NO
- Norway
- Prior art keywords
- blood
- plasma
- blood plasma
- type
- donors
- Prior art date
Links
- 210000002381 plasma Anatomy 0.000 title claims description 90
- 238000000034 method Methods 0.000 title claims description 15
- 238000002360 preparation method Methods 0.000 title description 9
- 239000008280 blood Substances 0.000 claims description 80
- 210000004369 blood Anatomy 0.000 claims description 78
- 241000700605 Viruses Species 0.000 claims description 8
- 238000004519 manufacturing process Methods 0.000 claims description 6
- 238000002156 mixing Methods 0.000 claims description 5
- 230000002779 inactivation Effects 0.000 claims description 4
- 239000000654 additive Substances 0.000 claims description 2
- 239000003146 anticoagulant agent Substances 0.000 claims description 2
- 229940127219 anticoagulant drug Drugs 0.000 claims description 2
- 238000006386 neutralization reaction Methods 0.000 claims description 2
- 239000003381 stabilizer Substances 0.000 claims description 2
- 238000004108 freeze drying Methods 0.000 claims 1
- 239000007788 liquid Substances 0.000 claims 1
- 238000001694 spray drying Methods 0.000 claims 1
- 239000003599 detergent Substances 0.000 description 4
- 239000000126 substance Substances 0.000 description 3
- 102000015081 Blood Coagulation Factors Human genes 0.000 description 2
- 108010039209 Blood Coagulation Factors Proteins 0.000 description 2
- DHMQDGOQFOQNFH-UHFFFAOYSA-N Glycine Chemical compound NCC(O)=O DHMQDGOQFOQNFH-UHFFFAOYSA-N 0.000 description 2
- 239000003114 blood coagulation factor Substances 0.000 description 2
- 239000003795 chemical substances by application Substances 0.000 description 2
- 210000003743 erythrocyte Anatomy 0.000 description 2
- 239000012467 final product Substances 0.000 description 2
- 238000001802 infusion Methods 0.000 description 2
- 150000002632 lipids Chemical class 0.000 description 2
- 239000000203 mixture Substances 0.000 description 2
- 239000002736 nonionic surfactant Substances 0.000 description 2
- 238000011176 pooling Methods 0.000 description 2
- 239000000047 product Substances 0.000 description 2
- 239000007858 starting material Substances 0.000 description 2
- OOSZCNKVJAVHJI-UHFFFAOYSA-N 1-[(4-fluorophenyl)methyl]piperazine Chemical compound C1=CC(F)=CC=C1CN1CCNCC1 OOSZCNKVJAVHJI-UHFFFAOYSA-N 0.000 description 1
- 102000004506 Blood Proteins Human genes 0.000 description 1
- 108010017384 Blood Proteins Proteins 0.000 description 1
- 239000004471 Glycine Substances 0.000 description 1
- 239000003463 adsorbent Substances 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 230000000740 bleeding effect Effects 0.000 description 1
- 239000003633 blood substitute Substances 0.000 description 1
- 210000004027 cell Anatomy 0.000 description 1
- 230000015271 coagulation Effects 0.000 description 1
- 238000005345 coagulation Methods 0.000 description 1
- 230000024203 complement activation Effects 0.000 description 1
- 230000004154 complement system Effects 0.000 description 1
- 230000000694 effects Effects 0.000 description 1
- 238000000605 extraction Methods 0.000 description 1
- 238000001914 filtration Methods 0.000 description 1
- 239000004023 fresh frozen plasma Substances 0.000 description 1
- 230000002209 hydrophobic effect Effects 0.000 description 1
- 230000000415 inactivating effect Effects 0.000 description 1
- 208000015181 infectious disease Diseases 0.000 description 1
- 230000002458 infectious effect Effects 0.000 description 1
- 239000000463 material Substances 0.000 description 1
- 239000012528 membrane Substances 0.000 description 1
- 238000009928 pasteurization Methods 0.000 description 1
- 239000011148 porous material Substances 0.000 description 1
- 238000003908 quality control method Methods 0.000 description 1
- 230000005855 radiation Effects 0.000 description 1
- 230000000717 retained effect Effects 0.000 description 1
- 229940074545 sodium dihydrogen phosphate dihydrate Drugs 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 239000008223 sterile water Substances 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Chemical compound O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
- A61K35/14—Blood; Artificial blood
- A61K35/16—Blood plasma; Blood serum
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
- A61P7/08—Plasma substitutes; Perfusion solutions; Dialytics or haemodialytics; Drugs for electrolytic or acid-base disorders, e.g. hypovolemic shock
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Hematology (AREA)
- Engineering & Computer Science (AREA)
- Cell Biology (AREA)
- Veterinary Medicine (AREA)
- Chemical & Material Sciences (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- General Chemical & Material Sciences (AREA)
- Biotechnology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Diabetes (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Biomedical Technology (AREA)
- Organic Chemistry (AREA)
- Developmental Biology & Embryology (AREA)
- Immunology (AREA)
- Virology (AREA)
- Zoology (AREA)
- Epidemiology (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- External Artificial Organs (AREA)
- Prostheses (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP97113466A EP0896824A1 (en) | 1997-08-05 | 1997-08-05 | A universally applicable blood plasma |
| PCT/EP1998/004841 WO1999007390A1 (en) | 1997-08-05 | 1998-08-04 | A universally applicable blood plasma |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| NO20000578D0 NO20000578D0 (no) | 2000-02-04 |
| NO20000578L NO20000578L (no) | 2000-03-27 |
| NO326216B1 true NO326216B1 (no) | 2008-10-20 |
Family
ID=8227172
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| NO20000578A NO326216B1 (no) | 1997-08-05 | 2000-02-04 | Et universalt anvendelig blodplasma og fremgangsmate for fremstilling derav. |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US20110008459A1 (ja) |
| EP (2) | EP0896824A1 (ja) |
| JP (1) | JP2001513507A (ja) |
| CN (1) | CN1272061A (ja) |
| AT (1) | ATE225665T1 (ja) |
| AU (1) | AU742427B2 (ja) |
| BG (1) | BG64350B1 (ja) |
| BR (1) | BR9811839A (ja) |
| CA (1) | CA2299421C (ja) |
| CZ (1) | CZ293726B6 (ja) |
| DE (1) | DE69808620T3 (ja) |
| DK (1) | DK0991416T4 (ja) |
| EA (1) | EA003182B1 (ja) |
| ES (1) | ES2185218T5 (ja) |
| HK (1) | HK1026146A1 (ja) |
| HU (1) | HU226548B1 (ja) |
| ID (1) | ID24308A (ja) |
| IL (1) | IL134308A (ja) |
| NO (1) | NO326216B1 (ja) |
| NZ (1) | NZ502661A (ja) |
| PL (1) | PL193983B1 (ja) |
| PT (1) | PT991416E (ja) |
| RS (1) | RS50016B (ja) |
| TW (1) | TW555563B (ja) |
| WO (1) | WO1999007390A1 (ja) |
Families Citing this family (21)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US6214221B1 (en) * | 1999-02-22 | 2001-04-10 | Henry B. Kopf | Method and apparatus for purification of biological substances |
| CN1207004C (zh) * | 2001-04-18 | 2005-06-22 | 马建川 | 通用型冻干血浆及其制备方法 |
| DK1696940T3 (da) * | 2003-12-19 | 2007-07-30 | Octapharma Ag | Universelt anvendeligt virus-inaktiveret blodplasma fremstillet fra portioner af ikke-kaukasisk plasma |
| EP1958618A1 (de) | 2007-02-15 | 2008-08-20 | Octapharma AG | Verfahren zur Gefriertrocknung mit optimierter Rekonstitution von Biopolymeren |
| AU2010234607B2 (en) * | 2009-04-09 | 2014-01-16 | Entegrion, Inc | Spray-dried blood products and methods of making same |
| US8407912B2 (en) | 2010-09-16 | 2013-04-02 | Velico Medical, Inc. | Spray dried human plasma |
| WO2011035062A2 (en) | 2009-09-16 | 2011-03-24 | Velico Medical, Inc. | Spray dried human plasma |
| FR2963737B1 (fr) * | 2010-08-16 | 2013-04-05 | Etat Francais Ministere De La Defense Service De Sante Des Armees | Procede de lyophilisation de plasma sanguin |
| US20140083628A1 (en) | 2012-09-27 | 2014-03-27 | Velico Medical, Inc. | Spray drier assembly for automated spray drying |
| EP2745922A3 (en) | 2010-10-29 | 2014-10-01 | Velico Medical, Inc. | System and Method for Spray Drying a Liquid |
| US9561184B2 (en) | 2014-09-19 | 2017-02-07 | Velico Medical, Inc. | Methods and systems for multi-stage drying of plasma |
| FR3026950A1 (fr) | 2014-10-09 | 2016-04-15 | Lab Francais Du Fractionnement | Procede de preparation de plasma universel |
| FR3035794B1 (fr) | 2015-05-06 | 2017-05-05 | Elicityl | Procede pour la purification du sang total ou d'un produit issu du sang |
| FR3035799B1 (fr) | 2015-05-06 | 2017-05-05 | Elicityl | Support pour la purification de liquides biologiques |
| WO2019074886A1 (en) | 2017-10-09 | 2019-04-18 | Terumo Bct Biotechnologies, Llc | LYOPHILIZATION CONTAINER AND METHOD OF USE |
| FR3083121B1 (fr) | 2018-06-27 | 2021-10-22 | Maco Pharma Sa | Procede de greffage d un element fibreux pour l elimination d anticorps du sang ou d un composant sanguin |
| US11609043B2 (en) | 2019-03-14 | 2023-03-21 | Terumo Bct Biotechnologies, Llc | Lyophilization container fill fixture, system and method of use |
| DE102020212609B3 (de) * | 2020-10-06 | 2022-04-07 | Universität Greifswald | Verfahren und Vorrichtung zur Herstellung von Universalplasma |
| US11975274B2 (en) | 2022-09-15 | 2024-05-07 | Velico Medical, Inc. | Blood plasma product |
| US11841189B1 (en) | 2022-09-15 | 2023-12-12 | Velico Medical, Inc. | Disposable for a spray drying system |
| US11998861B2 (en) | 2022-09-15 | 2024-06-04 | Velico Medical, Inc. | Usability of a disposable for a spray drying plasma system |
Family Cites Families (8)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US4664913A (en) * | 1982-05-24 | 1987-05-12 | Xoma Corporation | Method for treating plasma for transfusion |
| US4764369A (en) * | 1983-07-14 | 1988-08-16 | New York Blood Center Inc. | Undenatured virus-free biologically active protein derivatives |
| US4551435A (en) * | 1983-08-24 | 1985-11-05 | Immunicon, Inc. | Selective removal of immunospecifically recognizable substances from solution |
| JPH0723319B2 (ja) * | 1986-05-14 | 1995-03-15 | 株式会社ミドリ十字 | 血液製剤から血液型抗体を除去する方法 |
| DE4008852A1 (de) † | 1990-03-20 | 1991-09-26 | Octapharma Ag | Verfahren zur herstellung von nicht-infektioesem blutplasma |
| US5217627A (en) * | 1990-11-06 | 1993-06-08 | Pall Corporation | System and method for processing biological fluid |
| JP3575770B2 (ja) * | 1992-03-31 | 2004-10-13 | 学校法人藤田学園 | 血漿由来製剤 |
| AU667530B2 (en) * | 1992-05-28 | 1996-03-28 | New York Blood Center, Inc., The | Removal of antibodies from blood-derived compositions while retaining coagulation factors |
-
1997
- 1997-08-05 EP EP97113466A patent/EP0896824A1/en not_active Withdrawn
-
1998
- 1998-02-19 TW TW087102313A patent/TW555563B/zh not_active IP Right Cessation
- 1998-08-04 EA EA200000196A patent/EA003182B1/ru not_active IP Right Cessation
- 1998-08-04 CZ CZ2000370A patent/CZ293726B6/cs not_active IP Right Cessation
- 1998-08-04 WO PCT/EP1998/004841 patent/WO1999007390A1/en active IP Right Grant
- 1998-08-04 DK DK98945141T patent/DK0991416T4/da active
- 1998-08-04 EP EP98945141A patent/EP0991416B2/en not_active Expired - Lifetime
- 1998-08-04 ES ES98945141T patent/ES2185218T5/es not_active Expired - Lifetime
- 1998-08-04 NZ NZ502661A patent/NZ502661A/xx not_active IP Right Cessation
- 1998-08-04 CA CA002299421A patent/CA2299421C/en not_active Expired - Fee Related
- 1998-08-04 BR BR9811839-0A patent/BR9811839A/pt not_active Application Discontinuation
- 1998-08-04 RS YUP-58/00A patent/RS50016B/sr unknown
- 1998-08-04 CN CN98809602A patent/CN1272061A/zh active Pending
- 1998-08-04 PT PT98945141T patent/PT991416E/pt unknown
- 1998-08-04 HU HU0004795A patent/HU226548B1/hu not_active IP Right Cessation
- 1998-08-04 IL IL13430898A patent/IL134308A/en not_active IP Right Cessation
- 1998-08-04 DE DE69808620T patent/DE69808620T3/de not_active Expired - Lifetime
- 1998-08-04 ID IDW20000224A patent/ID24308A/id unknown
- 1998-08-04 JP JP2000506980A patent/JP2001513507A/ja active Pending
- 1998-08-04 AU AU92569/98A patent/AU742427B2/en not_active Ceased
- 1998-08-04 AT AT98945141T patent/ATE225665T1/de active
- 1998-08-04 PL PL98338794A patent/PL193983B1/pl not_active IP Right Cessation
-
2000
- 2000-02-01 BG BG104117A patent/BG64350B1/bg unknown
- 2000-02-04 NO NO20000578A patent/NO326216B1/no not_active IP Right Cessation
- 2000-08-31 HK HK00105463A patent/HK1026146A1/xx not_active IP Right Cessation
-
2010
- 2010-09-17 US US12/923,380 patent/US20110008459A1/en not_active Abandoned
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| NO326216B1 (no) | Et universalt anvendelig blodplasma og fremgangsmate for fremstilling derav. | |
| US20090092678A1 (en) | Universally applicable blood plasma | |
| KR0162094B1 (ko) | 혈소판 막 미립자 | |
| Wang et al. | Fibrin sealant reduces perioperative blood loss in total hip replacement | |
| JPH04501429A (ja) | ウイルスで汚染された薬理組成物中のウイルスの不活性化方法 | |
| KR20200015440A (ko) | 혈소판 분비물질을 함유하는 성장 인자들을 마련하는 방법 | |
| US9867852B2 (en) | Viral inactivated biological mixture | |
| HRP931496A2 (en) | Process for the preparation of biological preparations not containing (active) viruses | |
| TW201207113A (en) | Virally-inactivated growth factors-containing platelet lysate depleted of PDGF and VEGF and preparation method thereof | |
| US20170281679A1 (en) | Method for preparing universal plasma | |
| JPH09124507A (ja) | ウイルスを不活化した静脈内注射可能な免疫血清グロブリンの調製 | |
| US20110104298A1 (en) | Universally applicable virus inactivated blood plasma produced from portions of non-Caucasians plasma | |
| US4770877A (en) | Isolation of a high molecular weight aortic endothelial cell growth inhibitor | |
| Oberman et al. | Erythrocyte sensitization and anemia due to isoantibodies in lyophilized pooled plasma | |
| MXPA00001259A (en) | A universally applicable blood plasma | |
| Colvin et al. | Heat‐treated NHS factor VIII concentrate in the United Kingdom—a preliminary study | |
| Ockelford et al. | Controlled pore glass Factor VIII concentrate: influence of heat treatment | |
| CS270021B1 (cs) | 2působ přípravy nízkomolekulárnlch látek obsahujících imunomodulační aktivity z buněčných lyzátů lidských a zvířecích tkání, vylučující přítomnost infekčních agens a jejich toxických produktů | |
| CZ386991A3 (en) | combined process for preparing blood plasma free of infectious germs |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM1K | Lapsed by not paying the annual fees |